Track record · closed signal

Innoviva Inc (INVA) — closed signal from May 11, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 9, 2026 — -12.8% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$22.75 – $23.75Entry zone — fair-value band

$23.51Published — price the day we called it

$28.68Target — the price the thesis aimed for

$24.17Peak — highest point inside the window, not a realized return

$20.51Window close — end-of-window price, context only

What happened

Partial

Reached 13% of the predicted growth at its peak, without hitting the target.

At window close

-12.8%

realized, from the publication price to the last close inside the window

Peak gain

+2.8%

peak, from the publication price — not a realized return

S&P 500, same window

+4.9%

SPY over the identical days, dividend-adjusted

Window close

$20.51

last close inside the window, ended August 9, 2026

Peak price

$24.17

peak on June 24, 2026 — not a realized return

Days to target

—

The thesis — published May 11, 2026

Predicted growth

+22%

over the measurement window

Target price

$28.68

the price the thesis aimed for

Entry zone

$22.75 – $23.75

the fair-value band we waited for

Price at publication

$23.51

published May 11, 2026

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva looks attractive because it earns steady royalty cash, has plenty of cash on hand, and has beaten earnings estimates repeatedly, all while its valuation is not high. A recent research note reinforced the view that royalties should keep coming. Momentum is weak and trading volume is light, so the move is early and needs confirmation.

Primary drivers

Steady royalty income highlighted by the recent research note
Large cash balance lowers the need to raise capital
Consistent earnings beats support the durability of royalties
Thin trading volume means the move needs clearer confirmation

How it played out

INVA: the 22% growth thesis missed

Lyra published a short-term thesis at $23.51 and expected 22% growth toward $28.68. The thesis pointed to steady royalty income, ample cash, repeated earnings beats, and a modest valuation. It also noted weak momentum and light trading volume, so the move still needed confirmation.

The shares peaked at $24.17 on June 24, a 2.8% gain. They never reached the target. INVA ended the window at $20.51, below both the publication price and the stated entry zone. The thesis did not play out within the measurement window.

What happened during the window

On June 16, Innoviva announced an international distribution and licensing agreement with Dr. Reddy's for XACDURO. On August 5, the company reported $59.8 million in second-quarter royalty revenue and $36.6 million in U.S. product sales.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals